Christopher M Booth

List of Publications by Year
in descending order

202	7,274	76196	66788
papers	citations	40 h-index	78 g-index

203	203	203	10575
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Palliative Radiotherapy for Esophageal and Gastric Cancer: Population-Based Patterns of Utilization and Outcomes in Ontario, Canada. Journal of Palliative Care, 2023, 38, 157-166.	0.4	2
2	Incidence and Risk Factors of Venous Thromboembolism Following Hepatectomy for Colorectal Metastases: A Populationâ€Based Retrospective Cohort Study. World Journal of Surgery, 2022, 46, 180-188.	0.8	4
3	Trends in drug revenue among major pharmaceutical companies: A 2010â€2019 cohort study. Cancer, 2022, 128, 311-316.	2.0	9
4	Radiographic progression-free survival in the ACIS trial for prostate cancer. Lancet Oncology, The, 2022, 23, e4.	5.1	1
5	Contemporary clinical trials in hematologic cancer: Have we forgotten where we came from?. European Journal of Cancer, 2022, , .	1.3	0
6	Biased Evaluation in Cancer Drug Trialsâ€"How Use of Progression-Free Survival as the Primary End Point Can Mislead. JAMA Oncology, 2022, 8, 679.	3.4	25
7	Incidence, Timing, and Outcomes of Venous Thromboembolism in Patients Undergoing Surgery for Esophagogastric Cancer: A Population-Based Cohort Study. Annals of Surgical Oncology, 2022, 29, 4393-4404.	0.7	10
8	Rising Healthcare Costs and Utilization among Young Adults with Cirrhosis in Ontario: A Population-Based Study. Canadian Journal of Gastroenterology and Hepatology, 2022, 2022, 1-13.	0.8	2
9	ASO Visual Abstract: Incidence, Timing, and Outcomes of Venous Thromboembolism in Patients Undergoing Surgery for Esophagogastric Cancer: A Population-Based Cohort Study. Annals of Surgical Oncology, 2022, , 1.	0.7	0
10	Progression-free survival: it is time for a new name. Lancet Oncology, The, 2022, 23, 328-330.	5.1	24
11	The Time Toxicity of Cancer Treatment. Journal of Clinical Oncology, 2022, 40, 1611-1615.	0.8	77
12	Randomized Controlled Trials in Lung, Gastrointestinal, and Breast Cancers: An Overview of Global Research Activity. Current Oncology, 2022, 29, 2530-2538.	0.9	1
13	Cancer Risk and Mortality in Patients With Kidney Disease: A Population-Based Cohort Study. American Journal of Kidney Diseases, 2022, 80, 436-448.e1.	2.1	21
14	Prioritising locations for radiotherapy equipment in Brazil: a cross-sectional, population-based study and development of a LINAC shortage index. Lancet Oncology, The, 2022, 23, 531-539.	5.1	16
15	Cancer treatments should benefit patients: a common-sense revolution in oncology. Nature Medicine, 2022, 28, 617-620.	15.2	14
16	Priorities for cancer research in low- and middle-income countries: a global perspective. Nature Medicine, 2022, 28, 649-657.	15.2	101
17	Cancer in sub-Saharan Africa: a Lancet Oncology Commission. Lancet Oncology, The, 2022, 23, e251-e312.	5.1	94
18	Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class. JAMA Oncology, 2022, 8, 879.	3.4	14

#	Article	IF	Citations
19	Colorectal Cancer Treatment Characteristics and Concordance With Guidelines in Sri Lanka: Results From a Hospital-Based Cancer Registry. JCO Global Oncology, 2022, , .	0.8	2
20	Defining Essential Childhood Cancer Medicines to Inform Prioritization and Access: Results From an International, Cross-Sectional Survey. JCO Global Oncology, 2022, , .	0.8	2
21	Industry Relationships With Medical Oncologists: Who Are the High-Payment Physicians?. JCO Oncology Practice, 2022, 18, e1164-e1169.	1.4	13
22	ASO Author Reflections: Palliative Chemotherapy for Upper Gastrointestinal Cancer: Balancing Hope, Reality, Survival, and Symptoms. Annals of Surgical Oncology, 2021, 28, 88-89.	0.7	2
23	Symptom Evolution in Patients with Esophageal and Gastric Cancer Receiving Palliative Chemotherapy: A Population-Based Study. Annals of Surgical Oncology, 2021, 28, 79-87.	0.7	14
24	First-Line Palliative Chemotherapy for Esophageal and Gastric Cancer: Practice Patterns and Outcomes in the General Population. JCO Oncology Practice, 2021, 17, e1537-e1550.	1.4	6
25	Application of Value Frameworks to the Design of Clinical Trials: The Canadian Cancer Trials Group Experience. Journal of the National Cancer Institute, 2021, 113, 1422-1428.	3.0	1
26	Perioperative blood transfusion and resection of colorectal cancer liver metastases: outcomes in routine clinical practice. Hpb, 2021, 23, 404-412.	0.1	6
27	An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries. JAMA Oncology, 2021, 7, 379.	3.4	81
28	Long-Term Mental Health Service Utilization Among Survivors of Testicular Cancer: A Population-Based Cohort Study. Journal of Clinical Oncology, 2021, 39, 779-786.	0.8	15
29	Mental Health Resource Use Among Patients Undergoing Curative Intent Treatment for Bladder Cancer. Journal of the National Cancer Institute, 2021, 113, 1238-1245.	3.0	2
30	Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials. Current Oncology, 2021, 28, 1518-1527.	0.9	1
31	Evolution of the Randomized Clinical Trial in the Era of Precision Oncology. JAMA Oncology, 2021, 7, 728.	3.4	94
32	Utilization of imaging for active surveillance in testicular cancer: Is real-world practice concordant with guidelines?. Canadian Urological Association Journal, 2021, 16, .	0.3	4
33	Industry payments to US physicians for cancer therapeutics: An analysis of the 2016â€“2018 open payments datasets. Journal of Cancer Policy, 2021, 28, 100283.	0.6	5
34	Tracking the Workforce 2020-2030: Making the Case for a Cancer Workforce Registry. JCO Global Oncology, 2021, 7, 925-933.	0.8	1
35	Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib?. European Urology, 2021, 79, 710-712.	0.9	9
36	Choosing Wisely for COVID-19: ten evidence-based recommendations for patients and physicians. Nature Medicine, 2021, 27, 1324-1327.	15.2	12

#	Article	IF	Citations
37	Practicing on the edge of oncology: when standard of care feels uncomfortable. Nature Reviews Clinical Oncology, 2021, 18, 673-674.	12.5	1
38	Has the Current Oncology Value Paradigm Forgotten Patientsâ€™ Time?. JAMA Oncology, 2021, 7, 1757.	3.4	17
39	The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research. Lancet Oncology, The, 2021, 22, e369-e376.	5.1	25
40	The association of gender and persistent opioid use following an acute pain event: A retrospective population based study of renal colic. PLoS ONE, 2021, 16, e0256582.	1.1	2
41	Randomized Clinical Trials in the Era of Precision Oncologyâ€"The Role of End Points, Industry Funding, and Medical Writing Integrityâ€"Reply. JAMA Oncology, 2021, 7, 1579.	3.4	2
42	No Outcome Differences after Cystectomy between Patients with De Novo Muscle-Invasive Bladder Cancer Compared to Progressors: A Retrospective Population-Based Study. Journal of Urology, 2021, 206, 260-269.	0.2	2
43	Reply by Authors. Journal of Urology, 2021, 206, 268-269.	0.2	0
44	Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of ERBB2-Positive Metastatic Breast Cancer. JAMA Oncology, 2021, 7, e212140.	3.4	12
45	Perioperative Chemotherapy for Resectable Liver Metastases in Colorectal Cancer: Do We Have a Blind Spot?. Journal of Clinical Oncology, 2021, 39, 3767-3769.	0.8	8
46	Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. Lancet Oncology, The, 2021, 22, 1367-1377.	5.1	69
47	Healthcare delivery for non-communicable diseases among breast cancer survivors in Sri Lanka: Is there a missed opportunity?. Ecancermedicalscience, 2021, 15, 1301.	0.6	1
48	Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018. JAMA Internal Medicine, 2021, 181, 1596-1604.	2.6	14
49	Demographic, tumour, and treatment characteristics of female patients with breast cancer in Sri Lanka; results from a hospital-based cancer registry. BMC Cancer, 2021, 21, 1175.	1.1	7
50	Impact of the COVID-19 Pandemic on Cancer Researchers in 2020: A Qualitative Study of Events to Inform Mitigation Strategies. Frontiers in Public Health, 2021, 9, 741223.	1.3	7
51	Clinical Oncology Workload in Sri Lanka: Infrastructure, Supports, and Delivery of Clinical Care. JCO Global Oncology, 2021, 7, 1703-1710.	0.8	3
52	Value of Biomarker Expression for Randomized Clinical Trial Design: One (More) Missed Opportunity. Journal of Clinical Oncology, 2020, 38, 649-651.	0.8	2
53	Histology at transurethral resection of bladder tumor and radical cystectomy for bladder cancer: Insights from population-based data. Canadian Urological Association Journal, 2020, 15, 138-140.	0.3	3
54	Educational Status, Cancer Stage, and Survival in South India: A Population-Based Study. JCO Global Oncology, 2020, 6, 1704-1711.	0.8	8

#	Article	IF	Citations
55	Overview of Delivery of Cancer Care in Nepal: Current Status and Future Priorities. JCO Global Oncology, 2020, 6, 1211-1217.	0.8	26
56	Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer. JAMA Oncology, 2020, 6, 1751.	3.4	20
57	Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ, The, 2020, 371, m4087.	3.0	606
58	State of Cancer Control in Rwanda: Past, Present, and Future Opportunities. JCO Global Oncology, 2020, 6, 1171-1177.	0.8	23
59	Toward affordable cancer drugs: Do we need firmer price negotiation, me-too drugs, or a biosimilar silver bullet?. Seminars in Oncology, 2020, 47, 353-354.	0.8	0
60	Fibroblast Growth Factor Receptor 3 Mutation as a Prognostic Indicator in Patients with Urothelial Carcinoma: A Systematic Review and Meta-analysis. European Urology Open Science, 2020, 21, 61-68.	0.2	2
61	Factors Associated With Chemoradiation Therapy Interruption and Noncompletion Among Patients With Squamous Cell Anal Carcinoma. JAMA Oncology, 2020, 6, 881.	3.4	21
62	Trimodality Therapy for Muscle-Invasive Bladder Cancer: Concurrent Chemotherapy is Not Enough. Journal of Clinical Oncology, 2020, 38, 2709-2711.	0.8	8
63	Choosing Wisely for Cancer Care in India. Indian Journal of Surgery, 2020, 82, 6-8.	0.2	0
64	Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. Nature Reviews Clinical Oncology, 2020, 17, 268-270.	12.5	333
65	Informing Patients About Expected Outcomes: The Efficacy-Effectiveness Gap. Journal of Clinical Oncology, 2020, 38, 1651-1654.	0.8	50
66	Controversies in the management of clinical stage 1 testis cancer. Canadian Urological Association Journal, 2020, 14, E537-E542.	0.3	4
67	Risk of COVID-19 in Patients With Cancer. JAMA Oncology, 2020, 6, 1471.	3.4	5
68	Leveraging High-Quality Research to Define the Gastric Cancer Landscape in India. Indian Journal of Surgical Oncology, 2020, 11, 334-336.	0.3	1
69	â€œChoosing Wiselyâ€•for Cancer Care in India. Indian Journal of Surgical Oncology, 2020, 11, 4-6.	0.3	4
70	Real-world evidence and regulatory drug approval. Nature Reviews Clinical Oncology, 2020, 17, 271-272.	12.5	24
71	Statistical significance and clinical evidence â€“ Authors' reply. Lancet Oncology, The, 2020, 21, e119.	5.1	1
72	Childhood cancer care: closing equity gaps on the ground. Lancet Oncology, The, 2020, 21, 485-487.	5.1	4

#	Article	IF	Citations
73	Recommendations for Surgery During the Novel Coronavirus (COVID-19) Epidemic. Indian Journal of Surgery, 2020, 82, 124-128.	0.2	67
74	Improving access and quality of palliative care in Kerala: A cross-sectional study of providers in routine practice. Indian Journal of Palliative Care, 2020, 26, 500.	1.0	5
75	â€œChoosing Wiselyâ€•for cancer care in India. Journal of Cancer Research and Therapeutics, 2020, 16, 955.	0.3	0
76	Training of oncologists: results of a global survey. Ecancermedicalscience, 2020, 14, 1074.	0.6	4
77	â€œChoosing Wiselyâ€•for Cancer Care in India. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 567-569.	0.1	0
78	Estimating the optimal rate of adjuvant chemotherapy utilization for stage III colon cancer. Cancer Medicine, 2019, 8, 5590-5599.	1.3	3
79	Sociodemographic Factors and Stage of Cancer at Diagnosis: A Population-Based Study in South India. Journal of Global Oncology, 2019, 5, 1-10.	0.5	14
80	Undisclosed financial conflicts of interest among authors of American Society of Clinical Oncology clinical practice guidelines. Cancer, 2019, 125, 4069-4075.	2.0	30
81	Estimating the optimal perioperative chemotherapy utilization rate for muscleâ€•invasive bladder cancer. Cancer Medicine, 2019, 8, 6258-6271.	1.3	6
82	The Value of Progression-Free Survival as a Treatment End Point Among Patients With Advanced Cancer. JAMA Oncology, 2019, 5, 1779.	3.4	26
83	Real-world data: towards achieving the achievable in cancer care. Nature Reviews Clinical Oncology, 2019, 16, 312-325.	12.5	187
84	Cancer care workforce in Africa: perspectives from a global survey. Infectious Agents and Cancer, 2019, 14, 11.	1.2	34
85	Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma. Canadian Urological Association Journal, 2019, 13, 318-327.	0.3	8
86	Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value Assessment. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 374-387.	1.8	19
87	PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: A meta-analysis. Cancer Treatment Reviews, 2019, 76, 51-56.	3.4	36
88	From the $80 hamburger to managing conflicts of interest with the pharmaceutical industry. BMJ: British Medical Journal, 2019, 365, l1939.	2.4	7
89	Do not use robotic surgery in oncology patients when conventional surgical approaches are equally effective â€“ Authors' reply. Lancet Oncology, The, 2019, 20, e241.	5.1	1
90	Choosing Wisely India: ten low-value or harmful practices that should be avoided in cancer care. Lancet Oncology, The, 2019, 20, e218-e223.	5.1	47

#	Article	IF	Citations
91	Palliative Care and Symptom Burden in the Last Year of Life: A Population-Based Study of Patients with Gastrointestinal Cancer. Annals of Surgical Oncology, 2019, 26, 2336-2345.	0.7	32
92	Multiplicity in oncology randomised controlled trials: a threat to medical evidence?. Lancet Oncology, The, 2019, 20, 1638-1640.	5.1	9
93	Do doctors who order more routine medical tests diagnose more cancers? A populationâ€based study from Ontario Canada. Cancer Medicine, 2019, 8, 850-859.	1.3	7
94	Incidence of cirrhosis in young birth cohorts in Canada from 1997 to 2016: a retrospective population-based study. The Lancet Gastroenterology and Hepatology, 2019, 4, 217-226.	3.7	59
95	Medical oncology job satisfaction: Results of a global survey. Seminars in Oncology, 2019, 46, 73-82.	0.8	15
96	Delivery of chemotherapy for testicular cancer in routine practice: A population-based study. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 183.e17-183.e24.	0.8	3
97	Why patients receive treatments that are minimally effective?. Nature Reviews Clinical Oncology, 2019, 16, 3-4.	12.5	4
98	A mechanistic cohort study evaluating cognitive impairment in women treated for breast cancer. Brain Imaging and Behavior, 2019, 13, 15-26.	1.1	51
99	Medical oncology in India: Workload, infrastructure, and delivery of care. Indian Journal of Medical and Paediatric Oncology, 2019, 40, 121-127.	0.1	16
100	Cancer groundshot: going global before going to the moon. Lancet Oncology, The, 2018, 19, 288-290.	5.1	24
101	Pulmonary Metastasectomy for Colorectal Cancer: Predictors of Survival in Routine Surgical Practice. Annals of Thoracic Surgery, 2018, 105, 1605-1612.	0.7	21
102	Temporal trends in management and outcomes of testicular cancer: A populationâ€based study. Cancer, 2018, 124, 2724-2732.	2.0	20
103	Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration. Journal of the National Cancer Institute, 2018, 110, 486-492.	3.0	70
104	Perioperative chemotherapy for bladder cancer in the general population: Are practice patterns finally changing?. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 89.e13-89.e20.	0.8	45
105	Concurrent chemoradiotherapy for bladder cancer: Practice patterns and outcomes in the general population. Radiotherapy and Oncology, 2018, 127, 136-142.	0.3	10
106	What really matters at the end: perspectives from a patient, a family member and an oncologist. Cmaj, 2018, 190, E473-E475.	0.9	1
107	Palliative Care is Associated with Reduced Aggressive End-of-Life Care in Patients with Gastrointestinal Cancer. Annals of Surgical Oncology, 2018, 25, 1478-1487.	0.7	43
108	Documenting Goals of Care Among Patients With Advanced Cancer: Results of a Quality Improvement Initiative. Journal of Oncology Practice, 2018, 14, e557-e565.	2.5	11

#	Article	IF	Citations
109	Delivery of Global Cancer Care: An International Study of Medical Oncology Workload. Journal of Global Oncology, 2018, , 1-11.	0.5	32
110	Delivery of Pediatric Cancer Care in Mexico: A National Survey. Journal of Global Oncology, 2018, 4, 1-12.	0.5	6
111	Neoadjuvant chemotherapy for muscle-invasive bladder cancer: Underused across the 49th parallel. Canadian Urological Association Journal, 2018, 13, 29-31.	0.3	9
112	Venous Thromboembolism and Peri-Operative Chemotherapy for Muscle-Invasive Bladder Cancer: A Population-based Study. Bladder Cancer, 2018, 4, 419-428.	0.2	13
113	Reliability of Oncology Value Framework Outputs: Concordance Between Independent Research Groups. JNCI Cancer Spectrum, 2018, 2, pky050.	1.4	7
114	Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration Based on Single-Arm Trials. JAMA Oncology, 2018, 4, 1610.	3.4	27
115	Delivery of cancer care in Sri Lanka. Journal of Cancer Policy, 2018, 18, 20-24.	0.6	20
116	Use of radiotherapy for bladder cancer: A population-based study of evolving referral and practice patterns. Canadian Urological Association Journal, 2018, 13, 92-101.	0.3	4
117	The role of sex in the outcomes of patients with biliary tract cancers remains unclear: A population-based study. American Journal of Surgery, 2018, 216, 1118-1121.	0.9	1
118	Peri-Operative Chemotherapy for Bladder Cancer: A Survey of Providers to Determine Barriers and Enablers. Bladder Cancer, 2018, 4, 49-65.	0.2	8
119	Disease Characteristics, Clinical Management, and Outcomes of Young Patients With Colon Cancer: A Population-based Study. Clinical Colorectal Cancer, 2018, 17, e651-e661.	1.0	49
120	Diagnostic accuracy of magnetic resonance imaging for tumour staging of bladder cancer: systematic review and metaâ€analysis. BJU International, 2018, 122, 744-753.	1.3	60
121	Perioperative chemotherapy for urothelial carcinoma of the upper urinary tract: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2018, 128, 58-64.	2.0	27
122	Palliative Chemotherapy for Bladder Cancer: Treatment Delivery and Outcomes in the General Population. Clinical Genitourinary Cancer, 2017, 15, e535-e541.	0.9	10
123	Peri-operative allogeneic blood transfusion and outcomes after radical cystectomy: a population-based study. World Journal of Urology, 2017, 35, 1435-1442.	1.2	23
124	Approvals in 2016: questioning the clinical benefit of anticancer therapies. Nature Reviews Clinical Oncology, 2017, 14, 135-136.	12.5	33
125	Association Between Prognosis and Tumor Laterality in Early-Stage Colon Cancer. JAMA Oncology, 2017, 3, 1386.	3.4	73
126	Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. Lancet Oncology, The, 2017, 18, 887-894.	5.1	108

#	Article	IF	Citations
127	Neurotoxicity Outcomes in a Population-based Cohort of Elderly Patients Treated With Adjuvant Oxaliplatin for Colorectal Cancer. Clinical Colorectal Cancer, 2017, 16, 397-404.e1.	1.0	26
128	Management of stage <scp>III</scp> colon cancer in the elderly: Practice patterns and outcomes in the general population. Cancer, 2017, 123, 2840-2849.	2.0	24
129	Bladder-sparing radiotherapy for muscle-invasive bladder cancer: A survey of providers to determine barriers and enablers. Radiotherapy and Oncology, 2017, 125, 351-356.	0.3	7
130	Peri-operative blood transfusion for resected colon cancer: Practice patterns and outcomes in a population-based study. Cancer Epidemiology, 2017, 51, 35-40.	0.8	15
131	Temporal trends in the association between socioeconomic status and cancer survival in Ontario: a population-based retrospective study. CMAJ Open, 2017, 5, E682-E689.	1.1	37
132	Establishing achievable benchmarks for quality improvement in systemic therapy for earlyâ€stage breast cancer. Cancer, 2017, 123, 3772-3780.	2.0	9
133	The Final 30 Days of Life. Journal of Palliative Care, 2017, 32, 92-100.	0.4	22
134	Utilization of preâ€operative imaging for colon cancer: A populationâ€based study. Journal of Surgical Oncology, 2017, 115, 202-207.	0.8	4
135	Outcomes after repeat hepatic resection for recurrent metastatic colorectal cancer: A population-based study. American Journal of Surgery, 2017, 213, 1053-1059.	0.9	19
136	Benchmarking our urological care: Itâ€™s just the beginning. Canadian Urological Association Journal, 2017, 11, 223-4.	0.3	4
137	Perioperative chemotherapy for bladder cancer: A qualitative study of physician knowledge, attitudes, and behaviour. Canadian Urological Association Journal, 2017, 12, E182-90.	0.3	1
138	Setting Quality Improvement Priorities for Women Receiving Systemic Therapy for Early-Stage Breast Cancer by Using Population-Level Administrative Data. Journal of Clinical Oncology, 2017, 35, 3207-3214.	0.8	14
139	A randomized phase II study of pelareorep (REO) plus docetaxel vs. docetaxel alone in patients with metastatic castration resistant prostate cancer (mCRPC): Canadian Cancer Trials Group study IND 209.. Journal of Clinical Oncology, 2017, 35, 5021-5021.	0.8	1
140	Reliability of administrative data for evaluating the quality of systemic treatment for cancer.. Journal of Clinical Oncology, 2017, 35, 208-208.	0.8	1
141	Simultaneous resection of primary colorectal cancer and synchronous liver metastases: a population-based study. Canadian Journal of Surgery, 2017, 60, 122-128.	0.5	20
142	Chemotherapy for resected colorectal cancer pulmonary metastases: Utilization and outcomes in routine clinical practice.. Journal of Clinical Oncology, 2017, 35, 236-236.	0.8	0
143	Uptake and effectiveness of FOLFIRINOX for advanced pancreas cancer: A population-based study.. Journal of Clinical Oncology, 2017, 35, 245-245.	0.8	0
144	Prognostic impact of tumour laterality in early-stage colon cancer: A population-based study.. Journal of Clinical Oncology, 2017, 35, e15148-e15148.	0.8	0

#	Article	IF	Citations
145	Estimating the optimal rate of adjuvant chemotherapy utilization in stage III colon cancer.. Journal of Clinical Oncology, 2017, 35, 6591-6591.	0.8	0
146	Targeting the value of targeted therapy. Oncotarget, 2017, 8, 90612-90613.	0.8	1
147	Is there a measurable association of epidural use at cystectomy and postoperative outcomes? A population-based study. Canadian Urological Association Journal, 2016, 10, 321.	0.3	19
148	Increased incidence but improved median overall survival for biliary tract cancers diagnosed in Ontario from 1994 through 2012: A populationâ€based study. Cancer, 2016, 122, 2534-2543.	2.0	38
149	Use and Effectiveness of Adjuvant Chemotherapy for Stage III Colon Cancer: A Population-Based Study. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 47-56.	2.3	50
150	Delivery of Adjuvant Oxaliplatin for Colon Cancer: Insights From Routine Clinical Practice. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1548-1554.	2.3	7
151	Relevance of randomised controlled trials in oncology. Lancet Oncology, The, 2016, 17, e560-e567.	5.1	74
152	Stage III NSCLC â€" is it time to centralize care?. Nature Reviews Clinical Oncology, 2016, 13, 657-658.	12.5	2
153	The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis. Breast Cancer Research and Treatment, 2016, 160, 17-28.	1.1	102
154	Use of Palliative Chemotherapy for Advanced Bladder Cancer: Patterns of Care in Routine Clinical Practice. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 291-298.	2.3	4
155	Outcomes of Resected Colorectal Cancer Lung Metastases in Routine Clinical Practice: A Population-Based Study. Annals of Surgical Oncology, 2016, 23, 1057-1063.	0.7	17
156	Patterns of Referral for Adjuvant Chemotherapy for Stage II and III Colon Cancer: A Population-Based Study. Annals of Surgical Oncology, 2016, 23, 2529-2538.	0.7	7
157	Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Clinical Oncology, 2016, 34, 1945-1952.	0.8	202
158	Utilisation of preoperative imaging for muscleâ€invasive bladder cancer: a populationâ€based study. BJU International, 2016, 117, 430-438.	1.3	12
159	Risk factors and timing of venous thromboembolism after radical cystectomy in routine clinical practice: a populationâ€based study. BJU International, 2016, 118, 714-722.	1.3	23
160	Perioperative chemotherapy for muscle-invasive bladder cancer: Closing the gap between evidence and practice. Canadian Urological Association Journal, 2016, 10, 31.	0.3	1
161	Identifying opportunities to improve quality of cancer care: An evaluation of the use of diagnostic imaging in women curatively treated for early breast cancer (EBC).. Journal of Clinical Oncology, 2016, 34, 6603-6603.	0.8	0
162	Adjuvant chemotherapy for stage II colon cancer: Practice patterns and effectiveness in the general population.. Journal of Clinical Oncology, 2016, 34, 6569-6569.	0.8	0

#	Article	IF	Citations
163	Establishing achievable benchmarks for quality improvement in systemic therapy for early stage breast cancer.. Journal of Clinical Oncology, 2016, 34, 6591-6591.	0.8	0
164	Reasons for delay in time to initiation of adjuvant chemotherapy (TTAC) for colon cancer (CC): Analysis from six academic centers in Ontario, Canada.. Journal of Clinical Oncology, 2016, 34, 6541-6541.	0.8	0
165	Chemotherapy delivery for resected colorectal cancer liver metastases: Management and outcomes in routine clinical practice.. Journal of Clinical Oncology, 2016, 34, e18089-e18089.	0.8	0
166	Effects of a structured exercise program on physical activity and health-related fitness in colon cancer survivors: One year feasibility results from the NCIC CTG CO.21 (CHALLENGE) trial.. Journal of Clinical Oncology, 2016, 34, 3621-3621.	0.8	0
167	Cervical cancer screening and HPV vaccine acceptability among rural and urban women in Kilimanjaro Region, Tanzania. BMJ Open, 2015, 5, e005828-e005828.	0.8	98
168	Pathological factors associated with survival benefit from adjuvant chemotherapy (<scp>ACT</scp>): a populationâ€based study of bladder cancer. BJU International, 2015, 116, 373-381.	1.3	8
169	Is there a gender effect in bladder cancer? A population-based study of practice and outcomes. Canadian Urological Association Journal, 2015, 9, 269.	0.3	21
170	The Role of Population-Based Observational Research in Bladder Cancer. Bladder Cancer, 2015, 1, 123-131.	0.2	1
171	Radical Cystectomy and Adjuvant Chemotherapy for Bladder Cancer in the Elderly: A Population-based Study. Urology, 2015, 85, 791-798.	0.5	46
172	Benefits of Adjuvant Chemotherapy for Bladder Cancer. JAMA Oncology, 2015, 1, 727.	3.4	12
173	Reasons for Delay in Time to Initiation of Adjuvant Chemotherapy for Colon Cancer. Journal of Oncology Practice, 2015, 11, e28-e35.	2.5	28
174	Use of Preoperative Magnetic Resonance Imaging for Breast Cancer. JAMA Oncology, 2015, 1, 1238.	3.4	43
175	Management and Outcome of Colorectal Cancer Liver Metastases in Elderly Patients. JAMA Oncology, 2015, 1, 1111.	3.4	65
176	Outcomes of squamous histology in bladder cancer: A population-based study. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 425.e7-425.e13.	0.8	45
177	Lymph node counts are valid indicators of the quality of surgical care in bladder cancer: A population-based study. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 425.e15-425.e23.	0.8	21
178	A Phase II Study of GW786034 (Pazopanib) With or Without Bicalutamide in Patients With Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2015, 13, 124-129.	0.9	14
179	Prognosis, treatment benefit, and goals of care: what do oncologists discuss with patients who have terminal cancer?. Journal of Clinical Oncology, 2015, 33, e20509-e20509.	0.8	0
180	Perioperative chemotherapy for muscleâ€invasive bladder cancer: A populationâ€based outcomes study. Cancer, 2014, 120, 1630-1638.	2.0	83

#	Article	IF	Citations
181	Patterns of referral for perioperative chemotherapy among patients with muscle-invasive bladder cancer: A population-based study. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1200-1208.	0.8	29
182	Delivering high-quality care to patients with muscle-invasive bladder cancer: Insights from routine practice in Ontario. Canadian Urological Association Journal, 2014, 8, 297.	0.3	3
183	Impact of Concomitant Chemotherapy on Outcomes of Radiation Therapy for Head-and-Neck Cancer: A Population-Based Study. International Journal of Radiation Oncology Biology Physics, 2014, 88, 115-121.	0.4	10
184	Reply. Urology, 2014, 84, 1056-1057.	0.5	0
185	Processes of Care and the Impact of Surgical Volumes on Cancer-specific Survival: A Population-based Study in Bladder Cancer. Urology, 2014, 84, 1049-1057.	0.5	46
186	Disease-free survival as an end-point in the treatment of solid tumours â€“ Perspectives from clinical trials and clinical practice. European Journal of Cancer, 2014, 50, 2298-2302.	1.3	25
187	Progression-free survival as an end-point in solid tumours â€“ Perspectives from clinical trials and clinical practice. European Journal of Cancer, 2014, 50, 2303-2308.	1.3	32
188	Why is perioperative chemotherapy for bladder cancer underutilized?. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 391-395.	0.8	15
189	Time to adjuvant chemotherapy and survival in nonâ€“small cell lung cancer. Cancer, 2013, 119, 1243-1250.	2.0	52
190	Optimizing care and outcomes of patients with muscle-invasive bladder cancer. Canadian Urological Association Journal, 2013, 7, 625.	0.3	1
191	Adjuvant Chemotherapy for Non-small Cell Lung Cancer: Practice Patterns and Outcomes in the General Population of Ontario, Canada. Journal of Thoracic Oncology, 2012, 7, 559-566.	0.5	25
192	Achieving the achievable in muscle-invasive bladder cancer. Canadian Urological Association Journal, 2012, 6, 251-252.	0.3	0
193	The impact of socioeconomic status on stage of cancer at diagnosis and survival. Cancer, 2010, 116, 4160-4167.	2.0	244
194	Adoption of Adjuvant Chemotherapy for Nonâ€“Small-Cell Lung Cancer: A Population-Based Outcomes Study. Journal of Clinical Oncology, 2010, 28, 3472-3478.	0.8	62
195	Translating New Medical Therapies Into Societal Benefit. JAMA - Journal of the American Medical Association, 2008, 300, 2177.	3.8	71
196	Adjuvant chemotherapy for resected non-small cell lung cancer. Journal of Thoracic Oncology, 2006, 1, 180-7.	0.5	14
197	Severe acute respiratory syndrome and critical care medicine: The Toronto experience. Critical Care Medicine, 2005, 33, S53-S60.	0.4	60
198	Rotation to Methadone After Opioid Dose Escalation. Journal of Pain and Palliative Care Pharmacotherapy, 2005, 19, 25-31.	0.5	17

#	Article	IF	Citations
199	Is This Patient Dead, Vegetative, or Severely Neurologically Impaired?. JAMA - Journal of the American Medical Association, 2004, 291, 870.	3.8	454
200	Communication in the Toronto critical care community: important lessons learned during SARS. Critical Care, 2003, 7, 405.	2.5	35
201	Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area. JAMA - Journal of the American Medical Association, 2003, 289, 2801.	3.8	1,188
202	Gastrointestinal promotility drugs in the critical care setting: A systematic review of the evidence*. Critical Care Medicine, 2002, 30, 1429-1435.	0.4	198